Market Overview
Size, mix, and discovery economics
- Brevintel analysis values the artificial intelligence in drug discovery market at USD 3.1 billion in 2025 ($3.1B), expanding from USD 4 billion in 2026 to USD 43.9 billion by 2035 ($43.9B) at a 30.5% CAGR during 2026-2035 and 2026–2035.
- Isomorphic Labs (Alphabet Inc.) led with over 3.2% market share in 2025; Isomorphic Labs, Insitro, Insilico Medicine, Recursion Pharma, and Schrödinger collectively held 11.8%.
- Software accounted for 67.9% of 2025 revenue and machine learning represented 82.6% of technology demand, leaving a fragmented field for infrastructure, chemistry, and AI-native developers.
- Computational methods are moving beyond isolated virtual screening toward integrated target discovery, molecular design, property prediction, and preclinical decision support.
- A 2024 assessment placed the cost of bringing a novel drug to market above USD 3.5 billion when failures and capital costs are included, following 2021 pharmaceutical R&D cycle analysis.
- AI platforms do not remove clinical risk, but they can concentrate laboratory capacity on candidates with stronger predicted binding, developability, or safety characteristics.
- Equity funding for AI in drug R&D reached USD 3.8 billion in 2024, supporting platform build-out and pipeline advancement alongside the 30.5% growth path.
- Oncology represented USD 1.4 billion in 2025, while molecular library screening generated USD 1.2 billion as the largest application.
Technical markers and regulatory context
- AlphaFold 3 broadened structure prediction to interactions involving proteins, small molecules, nucleic acids, and antibodies, improving structure-informed design versus protein-only models.
- Insilico Medicine reported Phase IIa findings for rentosertib in idiopathic pulmonary fibrosis on June 3, 2025, linking a generative-AI discovery program to a peer-reviewed clinical proof point.
- January 2025 draft guidance from the U.S. Food and Drug Administration addresses credibility of AI models used to support regulatory decisions for drugs and biological products.
- That January 7, 2025 framework noted experience with more than 500 submissions containing AI components between 2016 and 2023, without creating a separate approval route for discovery software.
- Traceability, data provenance, and model-performance documentation become more important when AI-derived evidence enters downstream development packages.
- Global cancer incidence reached 20.6 million new cases in 2024, and IARC projects 34.4 million cases by 2050, raising the value of computational prioritization in oncology.
- Brevintel analysis attributes the 30.5% CAGR to a shift from computational promise to operational relevance at the earliest, highest-uncertainty discovery decisions.
- Growth is likely to favor vendors that couple model performance with reproducible experimental validation, auditable datasets, and development-ready documentation.
Market Dynamics
Adoption drivers
- Complex chronic-disease biology is raising the value of computational prioritization, especially where conventional experimental screening is slow across a broad target space.
- Oncology generates large genomic, molecular, and clinical datasets, supporting concentration of AI discovery spending at USD 1.4 billion in 2025.
- Digitized biological data—structure databases, sequencing, phenotypic imaging, assay results, and literature—expand the usable discovery substrate beyond manual medicinal-chemistry review.
- AlphaFold 3 is particularly relevant because its modeling scope extends beyond isolated proteins to molecular interactions that influence binding and mechanism.
- NVIDIA released BioNeMo as an open framework for digital-biology workloads on November 18, 2024, enabling training and deployment of biological foundation models on accelerated infrastructure.
- Faster inference and more accessible model-development tools broaden the customer base beyond organizations that maintain dedicated internal high-performance computing environments.
- Isomorphic Labs announced a multi-target discovery collaboration with Novartis in January 2024, converting platform capability into contracted pharmaceutical demand.
- BenevolentAI reported additional target progression under its AstraZeneca collaboration in June 2024, including further work in systemic lupus erythematosus.
Constraints and evidence burden
- Drug discovery data are generated across laboratories, assay formats, cell systems, and protocols that may not be directly comparable, limiting transferability of AI outputs.
- Models trained on fragmented data can appear accurate in a narrow internal setting yet perform poorly when transferred to a new target, modality, or customer dataset.
- Historical assay results, failed compounds, and clinical biomarker data must be standardized and governed before model selection can create repeatable value.
- Regulatory and ethical concerns raise the burden of evidence around AI-derived decisions, even though discovery tools are not regulated as products simply because they use AI.
- Black-box behavior, bias in training datasets, data-rights limitations, and uncertainty over intellectual-property ownership can slow adoption where recommendations lack an interpretable rationale.
- Brevintel analysis indicates that data infrastructure is a more durable constraint than algorithm availability, because accelerated compute does not correct inconsistent assays or incomplete negative-result data.
- Organizations that treat biological data as a governed product, with provenance and experimental context preserved, can improve both model performance and defensibility of downstream decisions.
- Vendors that cannot demonstrate this chain may still win exploratory projects, but they face a harder path to repeatable, development-stage contracts.
Segmentation Analysis
Component
- Software held 67.9% of market revenue in 2025 and is projected to expand at a 30.2% CAGR through licensed platforms for target identification, virtual screening, molecular generation, and property prediction.
- Cloud-based software represented 74.3% of software demand, allowing customers to scale intensive workloads without committing to permanent internal compute infrastructure.
- On-premise deployment remains relevant where proprietary compound libraries, sensitive patient data, or enterprise governance requirements limit external hosting.
- Services are projected to grow at a 31.1% CAGR, a faster rate that indicates demand for scientific interpretation, model customization, data curation, and experimental follow-through.
- The services shift is commercially important because compensation can align with defined program outcomes such as a validated target, optimized lead series, or preclinical candidate package.
- Software scale still anchors 67.9% of revenue, while the 31.1% services CAGR shows that licenses alone are not the full buying motion.
- Hybrid buying therefore combines the 30.2% software trajectory with services that convert model output into laboratory-ready work.
- Brevintel analysis treats component mix as a pairing of platform access and scientific follow-through rather than a binary software-versus-services split.
Technology
- Machine learning accounted for 82.6% of technology revenue in 2025, confirming data-trained models as the market’s core technology base.
- Deep learning made up 66.3% of the machine-learning segment, reflecting fit to graph, sequence, image, and multimodal data common in molecular and biological science.
- Deep-learning adoption is supported by structure-prediction advances such as AlphaFold 3 and the growing availability of accelerated foundation-model frameworks after November 18, 2024.
- Physics-based simulation retains a role as a mechanistic check on AI-generated hypotheses rather than becoming obsolete.
- Knowledge graphs can preserve interpretable biological relationships that support target reasoning alongside the 82.6% machine-learning share.
- The opportunity is increasingly hybrid: machine learning explores broad chemical or biological spaces, then more interpretable or physically grounded methods prioritize outputs for experimental testing.
- Model access is becoming less exclusive as cloud software at 74.3% of software demand and accelerated frameworks spread.
- Competitive advantage therefore depends increasingly on connecting models to proprietary biological data, synthesis-aware design, and fast experimental feedback.
Application and therapeutic area
- Molecular library screening generated USD 1.2 billion in 2025 and remains the largest application because it can be incorporated into established hit-finding workflows.
- Virtual screening reduces the number of compounds that need to be purchased, synthesized, or tested experimentally, offering a visible productivity case for organizations with large compound collections.
- Target identification is strategically significant because weak target biology is difficult to correct later, as illustrated by BenevolentAI’s AstraZeneca collaboration and June 2024 lupus target progression.
- De novo drug design is smaller but projected to expand at a 30.4% CAGR, the highest among applications.
- That 30.4% path depends on whether generated structures can meet potency, selectivity, synthesis, and developability requirements rather than merely appear novel in silico.
- Insilico Medicine’s rentosertib Phase IIa program, published June 3, 2025, is therefore a clinical proof point for generative design.
- Oncology led therapeutic areas with USD 1.4 billion in 2025, reinforced by heterogeneous genomic and phenotypic information and a 20.6 million new-case burden in 2024 heading toward 34.4 million by 2050.
- Neurodegenerative, inflammatory, infectious, metabolic, rare, and cardiovascular diseases create different data and validation conditions, so AI creates most value where it improves a clearly identified decision bottleneck.
End use
- Pharmaceutical and biotechnology companies held 52.8% of market revenue in 2025, using AI both to improve internal discovery productivity and to access specialized platforms through alliances.
- Their purchasing decisions are shaped by integration with existing data, compound libraries, therapeutic priorities, and development governance.
- CROs are projected to record a 31.0% CAGR, the fastest among end users, by embedding AI in screening, lead optimization, and preclinical support services.
- That 31.0% trajectory can expand adoption among smaller biotechs for which a direct enterprise software deployment would be too costly or technically demanding.
- Brevintel analysis suggests the most consequential segment interaction is between generative design at a 30.4% CAGR and outsourced discovery at a 31.0% CRO CAGR.
- Together those rates indicate that AI-native molecular design can reach smaller developers through project-based research engagements, not solely through direct platform subscriptions.
- CROs that can make the model-to-experiment loop operational may become an access channel for de novo design among customers with limited internal computational infrastructure.
- The 52.8% pharmaceutical and biotechnology share still anchors demand, but services-led access is the faster growth mechanism.
Regional Outlook
North America and Europe
- North America accounted for 47.7% of market revenue in 2025, supported by pharmaceutical R&D concentration, venture funding, advanced computing infrastructure, and AI drug-discovery companies.
- The U.S. generated USD 0.7 billion in 2022, USD 0.8 billion in 2023, USD 1.1 billion in 2024, and USD 1.4 billion in 2025.
- January 2025 FDA work on AI-related regulatory considerations gives U.S. sponsors a direct channel for engaging evidence standards likely to affect AI-supported development.
- Canada contributes a distinct research and platform-development base, illustrated by the 2025 collaboration between Variational AI and Merck.
- Europe generated USD 1.0 billion in 2025, combining established pharmaceutical buyers with a large academic and computational-biology base.
- The UK has particular relevance through Isomorphic Labs and BenevolentAI, whose Novartis and AstraZeneca-related activity created globally relevant discovery partnerships after January 2024 and June 2024.
- Germany, France, Spain, Italy, the Netherlands, and the rest of Europe contribute through pharmaceutical manufacturing, life-sciences research, digital-health infrastructure, and cross-border networks.
- Sanofi’s participation in Enveda’s Series C financing in February 2025 illustrates continued European pharmaceutical interest in AI-enabled discovery platforms.
Asia Pacific, Latin America, and Middle East & Africa
- Asia Pacific is the fastest-growing region, with a projected 31.2% CAGR, reflecting a lower starting point plus rising access to cloud computing and global AI platforms.
- China combines growing biopharma capacity with clinical-development scale, while Japan offers established pharmaceutical companies and a mature external-partnership market.
- Insilico Medicine’s clinical work across China and Australia, including rentosertib and the 2025 Phase I update for ISM5411, shows AI-originated programs can use the region for development execution and diversified evidence.
- India’s opportunity is closely linked to its CRO and technical-services base, adding computational screening, design, and prediction to established research delivery models.
- Australia and South Korea strengthen the region through clinical research infrastructure, research institutions, and technology adoption.
- Latin America remains a smaller market led by Brazil, Mexico, Argentina, and the rest of the region, progressing mainly through research institutions, multinational relationships, and CRO models.
- Middle East & Africa is an early-stage market encompassing South Africa, Saudi Arabia, the UAE, and the rest of the region, with opportunity concentrated in research infrastructure and cloud-enabled modeling.
- Brevintel analysis expects Asia Pacific’s 31.2% CAGR to narrow, but not immediately erase, the revenue gap with North America’s 47.7% share and Europe’s USD 1.0 billion 2025 base.
Competitive Landscape
Structure and positioning
- The market remains fragmented, with the five largest participants collectively accounting for approximately 11.8% of 2025 revenue after Isomorphic Labs’ over 3.2% lead.
- Competition occurs across AI infrastructure and cloud delivery, computational chemistry and simulation, target discovery and molecular design, disease-specific platforms, and integrated discovery-to-clinic models.
- Isomorphic Labs, an Alphabet company, is positioned around structure-informed design; its USD 600 million Series A financing in March 2025 and collaborations with Novartis and Eli Lilly illustrate partnership-led economics.
- Microsoft and NVIDIA operate primarily at the enabling-infrastructure layer, with BioNeMo tools released November 18, 2024 reducing integration burden for scalable biological models.
- IBM brings enterprise AI, hybrid-cloud, and scientific-computing capabilities to customers that require data governance alongside scalable analytics.
- Schrödinger reported USD 199.5 million in software revenue and USD 56.4 million in drug-discovery revenue in 2025, combining physics-based simulation with AI-supported discovery.
- Recursion Pharmaceuticals described a 2024 annual-report pipeline and platform strategy that extends AI across discovery and development, while Recursion Pharma remains among the named top-five participants.
- Insilico Medicine differentiated through Pharma.AI, rentosertib Phase IIa results dated June 3, 2025, the 2025 Phase I update for ISM5411, and integration of its Nach01 model with Microsoft Discovery.
- BenevolentAI’s knowledge-graph approach remains centered on biological target discovery and partnership outputs, including continued AstraZeneca progress after June 2024.
- Atomwise focuses on structure-based binding prediction; Insitro combines machine learning with high-throughput human cellular models; Deep Genomics, Iktos, and Deargen occupy RNA, generative-design, and Asia-Pacific interaction niches.
Integrated producers
- Isomorphic Labs (Alphabet Inc.)
- Microsoft
- NVIDIA
- IBM
- Schrödinger
- Recursion Pharmaceuticals
- Insilico Medicine
Specialty suppliers
- Insitro
- BenevolentAI
- Atomwise
- Deep Genomics
- Iktos
- Deargen
- 9Bio Therapeutics
- Aureka Biotechnologies
- CellCodex Technology Limited
- chAIron
- DenovAI Biotech
- Examol